● Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Condition: Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC · Sponsor: Revolution Medicines, Inc.

PhasePhase 3

Planned participants670

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Revolution Medicines Study Director · 1-844-2-REVMED · medinfo@revmed.com

Always discuss trial participation with your own doctor first.

Locations (4)

Moffitt Cancer Center	Tampa, Florida, United States	Recruiting
Piedmont Healthcare	Atlanta, Georgia, United States	Recruiting
University of Chicago Medical Center	Chicago, Illinois, United States	Recruiting
Johns Hopkins University	Baltimore, Maryland, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07621718